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Ovarian clear cell carcinoma
A B S T R A C T
SWI/SNF chromatin remodeling complexes play an important role in the epigenetic regulation of chromatin
structure and gene transcription. Mutual exclusive subunits in the SWI/SNF complex include the DNA targeting
members ARID1A and ARID1B as well as the ATPases SMARCA2 and SMARCA4. SWI/SNF complexes are mu-
tated across many cancer types. The highest mutation incidence is found in ARID1A, primarily consisting of
deleterious mutations. Current advances have reported synthetic lethal interactions with the loss of ARID1A in
several cancer types. In this review, we discuss targets that are only important for tumor growth in an ARID1A
mutant context. We focus on synthetic lethal strategies with ARID1A loss in ovarian clear cell carcinoma, a
cancer with the highest ARID1A mutation incidence (46–57%). ARID1A directed lethal strategies that can be
exploited clinically include targeting of the DNA repair proteins PARP and ATR, and the epigenetic factors EZH2,
HDAC2, HDAC6 and BRD2.
1. Introduction
ATP dependent chromatin remodeling is an epigenetic process
regulating gene transcription in which chromatin structure can be co-
ordinated through mobilization of nucleosomes. The evolutionary
conserved ATP dependent chromatin remodelers consist of four sub-
classes. These are Imitation SWI (ISWI), INO80, nucleosome remodeling
and histone deacetylase Mi2/CHD (NURD/Mi2/CHD) and switch su-
crose non-fermenting (SWI/SNF) and are involved in diverse cellular
processes such as tissue diﬀerentiation, proliferation and DNA repair
[1]. While all chromatin remodelers contain ATPase domains, addi-
tional subunits diﬀer per subclass and are important for modulation of
ATPase activity and chromatin complex recruitment onto tissue-speciﬁc
genomic loci. SWI/SNF chromatin remodeling complexes are im-
plicated in many stages of pluripotency and tissue diﬀerentiation along
mammalian development. Compared to the SWI/SNF subclass, the role
of ISWI, INO80 and Mi2/CHD chromatin remodeling complexes in
these processes is limited but supplementary to SWI/SNF (for a review
see Hota et al. [2]). BAF SWI/SNF chromatin remodeling complexes
contain multiple subunits with mutual exclusive characteristics, which
include the DNA targeting subunits ARID1A and ARID1B, and the AT-
Pase subunits SMARCA2 and SMARCA4 (Fig. 1). These mutual
exclusive members discriminate BAF SWI/SNF complexes from coun-
terpart PBAF SWI/SNF complexes that contain SMARCA4 but not the
other three proteins. BAF and PBAF SWI/SNF complexes have distinct
regulatory roles in lineage development. For instance, BAF speciﬁc
SMARCA2 plays a key role in smooth muscle formation, while the PBAF
speciﬁc subunit ARID2 is important for coronary morphogenesis. More
SWI/SNF subunits have been shown to coordinate speciﬁc develop-
mental processes [2]. Therefore, it is conceivable that a speciﬁc subunit
mutation causes changes in SWI/SNF chromatin binding at typical
transcriptional enhancer sites, which ultimately results in loss of dif-
ferentiation potential and drives cells into a proliferative state [3]. Over
20% of cancers contain a mutation in at least one of the members of the
15-subunit BAF SWI/SNF complex (hereinafter referred to as SWI/SNF)
[4]. Especially ARID1A and ARID1B and SMARCA2 and SMARCA4 have
high mutation frequencies and are suggested to be driver mutations in
multiple cancers [5, 6]. The mutation incidence in SWI/SNF subunits
varies per tumor type, indicative for distinct roles of SWI/SNF com-
plexes in human tissues. For instance, ARID1A deﬁcient mice are re-
sistant to hepatocellular carcinoma initiating agents while mice with
established hepatocellular carcinoma showed enhanced metastasis
upon ARID1A loss [7]. Conversely, ARID1A mutations promote color-
ectal tumor formation, indicating the context dependent eﬀect of
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ARID1A loss [8]. ARID1A is the most frequently mutated SWI/SNF
complex member. The highest alteration incidence, 46–57%, is found in
ovarian clear cell carcinoma (OCCC) [9–11]. Other tumor types har-
boring ARID1A mutations comprise uterine endometrioid carcinoma
(47–60%), ovarian endometrioid carcinoma (30%), gastric cancer
(29%), colorectal cancer (5–10%) and pancreatic cancer (3–5%) [6,
12–14]. Tumors with mutations in ARID1B include OCCC (18%), col-
orectal cancer and gastric cancer (5–10%) (Fig. 2). Mutations in
SMARCA2 are found in colorectal cancer, lung cancer (3–5%) and
OCCC (2%). Mutations in SMARCA4 are found in melanoma, lung
cancer (5–10%) and OCCC (5%) [6, 15] (Fig. 3).
In this review, we discuss recent developments in strategies that
take advantage of cellular dependencies speciﬁc for ARID1A mutant
cancers. This concept, named synthetic lethality, describes a relation
between two genes in which cells remain viable after loss of either gene
alone but loss of both genes will result in a lethal phenotype [16].
Synthetic lethal targets, including proteins involved in DNA repair and
epigenetic regulation are reviewed, focusing on targets recently iden-
tiﬁed in ARID1A mutant OCCC.
2. Role of ARID1A in ovarian clear cell carcinoma
Mutations in ARID1A are often heterozygous nonsense or frame-
shifts that are not enriched in hotspot sites [9, 10]. ARID1A mutations,
homo- or heterozygous, coincides with loss of ARID1A protein expres-
sion in OCCC. This suggests haploinsuﬃciency or the occurrence of
other mechanisms that are responsible for complete loss of protein
expression, such as epigenetic silencing, mutations in non-coding re-
gions or post transcriptional mechanisms [9, 17–20]. Additionally, two
studies described loss of ARID1A protein expression in precursor lesions
of OCCC, i.e. ovarian endometriosis, indicating that ARID1A loss is an
early event in progression to OCCC [21, 22]. Two studies described a
worse progression-free survival in ARID1A deﬁcient OCCC patients.
However, literature consistently showed that overall survival in OCCC
is not predicted by ARID1A status [11, 23–25].
ARID1A−/− or ARID1A+/− knockout causes lethality in early em-
bryonic mouse development [26]. In contrast, depletion of ARID1A
expression induced proliferation in ovarian surface epithelium cells.
Another study showed that knockdown of ARID1A provided phenotypic
changes associated with neoplastic transformation in an immortalized
endometriosis cell line [27]. Upon ARID1A knockdown the expression
of 99 genes was up or downregulated. Many of these genes are also
dysregulated in OCCC tumors [28]. Still, ARID1A loss itself is not suf-
ﬁcient to induce tumorigenesis in the ovaries of conditional Cre-Lox
mouse models. Only mice with combined ARID1A and PTEN loss de-
veloped ovarian hyperplasia, which progressed to tumors in 59% [29].
Another study showed that additional ARID1A−/− or ARID1A+/−
knockout in APC and PTEN null mice actually delayed ovarian tumor
formation but promoted epithelial diﬀerentiation and metastasis [30].
Moreover, Chandler et al. demonstrated that ovarian tumor formation
only occurred in mice with concurrent homozygous knockout of
ARID1A and PIK3CAH1047R missense mutation. These tumors mani-
fested an OCCC like histopathology and gene expression signature.
Furthermore, a mechanistic link was identiﬁed between ARID1A loss
and PIK3CA activation with the induction of cytokine expression, in-
cluding IL-6, via NF-ƙB signaling [31]. In vitro and in vivo suppression
of IL-6 reduced the tumor cell proliferation, presenting IL-6 blocking as
potential synthetic lethal strategy in an ARID1A and PIK3CA mutant
Fig. 1. SWI/SNF complex members. ARID1A and ARID1B are mutual ex-
clusive core components in the mammalian BAF SWI/SNF chromatin re-
modeling complex. Other core members are shown in turquoise and ex-
changeable components in yellow. (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. ARID1A and ARID1B alterations in cancer.
Alteration frequencies of ARID1A and ARID1B in
published and provisional datasets incorporated in
cBioPortal are depicted with a 10% cutoﬀ (http://
cbioportal.org downloaded 3-10-2017). Of note,
ARID1A and ARID1B mutations are commonly found
in several cancer types, but not always displayed due
to the cutoﬀ.
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OCCC background [32].
3. Mutual exclusive roles for ARID1A and ARID1B
The SWI/SNF subunits encoding genes ARID1A and ARID1B share
60% sequence identity but are thought to have disparate roles in cell
cycle regulation [33]. ARID1B mutations are less prevalent in cancer
with fewer deleterious mutations as compared to ARID1A (Fig. 2). In
2007, Nagl et al. reported opposing roles for ARID1A and ARID1B in
regulating proliferation in osteoblasts. They found that ARID1B had a
more proliferation inducing role via MYC and Cyclin E activation as
compared with ARID1A [34]. ARID1A loss modiﬁes chromatin acces-
sibility in colorectal cancer cells and this accessibility is further mod-
iﬁed by loss of ARID1B. In the presence of wild-type ARID1A, ARID1B
loss did not have an eﬀect on chromatin accessibility, indicating a
dominant eﬀect of ARID1A. It was reported that ARID1B in the absence
of ARID1A facilitates expression of proliferative genes involved in
PI3K/AKT/mTOR and ERBB receptor tyrosine kinase signaling in col-
orectal carcinoma and OCCC cells [35]. These ﬁndings hypothesize that
redundant incorporation of ARID1B in residual SWI/SNF complexes in
ARID1A deﬁcient cells could stimulate proliferation. The consecutive
discovery that ARID1A mutant tumors are speciﬁcally vulnerable to
ARID1B loss was based on the Achilles project, a loss of function genetic
screen database, which includes over 200 cancer cell lines [36]. Sub-
sequently, Helming et al. demonstrated a reduced proliferation in two
ARID1Amutant OCCC cell lines after shRNA induced ARID1B loss. They
found a destabilization of full size SWI/SNF complexes after loss of both
proteins, suggesting that depletion of intact SWI/SNF complexes is re-
sponsible for the observed synthetic lethality. Co-mutations in ARID1A
and ARID1B do occur but never biallelic in both genes, indicating some
ARID1 function is essential for cell survival of both cancer and normal
cells [36].
4. ARID1A-directed synthetic lethality
Several studies have shown that ARID1A-directed synthetic lethality
can be attained through diverse molecular mechanisms. These synthetic
lethal interactions with ARID1A mutations go beyond direct targeting
of ARID1B.
4.1. Lethal relationship between ARID1A loss and inhibition of the DNA
damage response
Besides ARID1A's regulatory role in SWI/SNF complex binding to
DNA, it is also involved in DNA double-strand break (DSB) repair.
Initially, the SWI/SNF ATPase subunits SMARCA2 and SMARCA4 were
described to interact with the DSB localizing protein γ-H2AX upon DSB
formation, suggesting a role for SWI/SNF in the DNA damage response
(DDR) [37]. Recently, ARID1A and ARID1B were found to localize to
DSBs and facilitate non-homologous end joining (NHEJ) and ARID1A
was assigned a role in homologous recombination (HR) [38, 39]. NHEJ
is the more error prone DSBs repair mechanism compared to HR.
ARID1A and ARID1B recruit the NHEJ proteins KU70 and KU80 to the
site of DNA damage and are thus involved in this type of DSB repair at
an early stage. Downregulation of ARID1A or ARID1B sensitized os-
teosarcoma cells and immortalized pancreatic ductal epithelial cells to
DSB inducing treatments such as oxaliplatin and cisplatin [38, 40]. Two
studies have investigated synthetic lethality approaches based on tar-
geting of DDR proteins in ARID1Amutant cancers. Shen et al. identiﬁed
a role for ARID1A in DSB repair as binding partner of ATR, a DDR
central regulator involved in DSB and single strand DNA breaks [39].
With chromatin immunoprecipitation assays they found ARID1A to be
enriched at chromatin regions close to DSBs, a recruitment that was lost
upon ATR inhibition. Phenotypically, ARID1A stopcodon introduction
in HCT116 colorectal carcinoma cells resulted in impaired G2/M
checkpoint control upon irradiation-induced DSBs. Cells lacking
ARID1A more frequently re-entered the cell cycle after irradiation as
compared with control cells. The phosphorylation of ATR and CHK1,
another DDR protein important in G2/M checkpoint control, was re-
duced in ARID1A mutant cells, indicating that ARID1A is involved in
G2/M progression. Furthermore, ARID1A loss reduced localization of
the DDR adaptor proteins γ-H2AX and 53BP1 at the site of DSBs. Col-
lectively, they reveal an important role for ARID1A to conduct ATR-
mediated DDR signaling required for HR (Fig. 4). It is unclear if ARID1A
Fig. 3. SMARCA2 and SMARCA4 alterations in
cancer. Alteration frequencies of SMARCA2 and
SMARCA4 in published and provisional datasets in-
corporated in cBioPortal are depicted with a 10%
cutoﬀ (http://cbioportal.org downloaded 3-10-
2017). Of note, SMARCA2 and SMARCA4 mutations
are commonly found in several cancer types, but not
always displayed due to the cutoﬀ.
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alone or in complex with other SWI/SNF members localizes to DSBs and
activates ATR and subsequent DDR. The involvement of ARID1A in DSB
repair led Shen et al. to test for synthetic lethality of PARP inhibitors in
ARID1A mutant cells as these inhibitors are known to be lethal in cells
with DSB repair deﬁciencies, such as BRCA1/2 mutations. Multiple
inhibitors of PARP provided toxicity in (BRCA wild-type) isogenic pairs
of ARID1A-depleted non-transformed breast epithelial, breast epithelial
carcinoma and colorectal carcinoma cells and a panel of ovarian car-
cinoma cell lines, showing more than three-fold reduced colony for-
mation in ARID1A-depleted cell lines. Additionally, PARP treatment
eﬃcacy was detected in (BRCA wild-type) ARID1A-depleted xenograft
models of breast and colorectal cancer [39].
In another study by Williamson et al., RNAi screening libraries
identiﬁed ARID1A loss as a genetic determinant of sensitivity to ATR
inhibition in the triple negative (ER, PR and ERBB2 negative) breast
cancer cell line HCC1143 and immortalized normal mammary epithe-
lial cell line MCF12A [41]. ARID1A loss in combination with ATR in-
hibition by VX-970 was conﬁrmed to be over three-fold more eﬀective
in multiple cancer lineages, including several OCCC cell lines and an
isogenic ARID1A-deﬁcient pair of the colorectal cancer cell line
HCT116. Sensitivity to ATR inhibition was observed in xenograft
models of the isogenic HCT116 cancer cell line pair and to a lesser
extent in the xenograft model of ARID1A mutant TOV21G OCCC cells.
In this study, it was also demonstrated that ARID1A loss in HCT116
cells resulted in accumulation of cells in G2/M. In line with this result,
ARID1A mutant HCT116 xenografts showed reduced tumor growth. In
the presence of ATR inhibitors, they found reduced accumulation of
ARID1A mutant HCT116 cells in G2/M and multiple indications of
chromosomal instability and apoptosis induction in these cells [41].
Previously, it was reported that SMARCA4 deprived mouse em-
bryonic stem cells have decreased DNA localization of DNA topoi-
somerase 2-alpha (TOP2A), an enzyme important in DNA transcription
and translation [42]. Elaborating on this study, Williamson et al. found
ARID1A mutant HCT116 cells to have decreased TOP2A DNA locali-
zation as well, indicating that SWI/SNF complexes are important for
stable function of TOP2A [41]. Since ARID1A status did not determine
TOP2A expression, more likely, SWI/SNF complexes directly bind to
TOP2A via ARID1A, which is important for the localization of TOP2A to
at least 12.000 genomic loci, as demonstrated earlier (Fig. 4) [42].
4.2. Epigenetic targeting and ARID1A synthetic lethality
Synthetic lethality between ARID1A loss and inhibition of multiple
distinct epigenetic proteins was recently found in OCCC. The lethal
interaction between ARID1A mutation and inhibition of polycomb re-
pressive complex 2 (PRC2) catalytic subunit EZH2 resulted in the ﬁrst
therapeutically druggable target for ARID1A mutant cancers [43]. In
contrast to SWI/SNF complexes that generate a more open chromatin
structure, PRC2 closes chromatin by methylation of histone 3 lysine 27
(H3K27me3), which is associated with gene repression [44]. Disruption
of epigenetic chromatin remodeling is suggested to drive oncogenesis in
tumors that lack genomic instability [1]. Therefore, Bitler et al. pre-
sumed ARID1A mutant OCCC depend on epigenetic mechanisms, since
genomic instability is lower compared with ARID1A wild-type OCCC. A
panel of HDAC and EZH2 inhibitors was tested on RMG1 OCCC cells
with ARID1A knockdown in 3D matrigel cultures. The highest tumor
sphere reduction was achieved by GSK126, an inhibitor of EZH2
H3K27Me3 methyltransferase activity. Treated tumor spheres showed
loss of the proliferation marker Ki67 and increased apoptosis. Similar
results were found in xenografts. Approximately two-fold increase in
GSK126 sensitivity was observed in ARID1A mutant (n=4) versus
ARID1A wild-type (n=3) OCCC 3D cell line models. Gene expression
proﬁling of ARID1A mutant cells treated with GSK126 identiﬁed
PIK3IP1, a negative regulator of PI3K/AKT/mTOR signaling, as a me-
chanistic link for the synthetic lethality between ARID1A loss and EZH2
inhibition [45]. PIK3IP1 was found to be downregulated upon ARID1A
loss. After ARID1A loss EZH2 methyltransferase induced H3K27Me3
methylation of the PIK3IP1 gene thus preventing expression of PIK3IP1,
which is then followed by induction of PI3K/AKT/mTOR signaling and
proliferation (Fig. 4). GSK126-induced loss of the PIK3IP1 promoter
H3K27Me3 mark resulted in PIK3IP1 expression and lethality, de-
monstrating the addiction of ARID1Amutant ovarian cancer cells to low
PIK3IP1 levels [43]. Consecutive work indicated that ARID1A mutant
OCCC is selectively susceptible to inhibition of HDAC2, a known
binding partner of the EZH2-containing PRC2 complex [46]. As it turns
out, HDAC2 only interacts with this complex in the absence of ARID1A.
In line with the observations on EZH2 inhibition, knockdown of HDAC2
or chemical inhibition of HDAC2, using the non-speciﬁc HDAC inhibitor
vorinostat, caused re-expression of PIK3IP1 in ARID1A mutant OCCC
cells, which resulted in reduced proliferation and increased apoptosis.
Vorinostat IC50 was 10-fold lower in ARID1A mutant (n=4) versus
ARID1A wild-type (n=4) ovarian cancer cell lines. Similar results were
observed with two primary cultures.
For clinical applicability it will be important to know if the synthetic
lethal interaction between ARID1A loss and HDAC2 or EZH2 inhibition
holds true in a larger set of OCCC models and in other tumor lineages.
To this end, EZH2 inhibition was found to be lethal in lung, adrenal
gland and renal carcinoma cell lines with mutations in the SWI/SNF
components ARID1A, PBRM1 and SMARCA4 [47]. Kim et al. propose
that SWI/SNF mutant tumors could generally depend on EZH2 activity.
Their data suggests that EZH2 inhibition is only lethal when the EZH2-
PRC2 complex interaction is destabilized, an eﬀect which GSK126 did
not achieve in all cell lines. Based on the Achilles project they ad-
ditionally showed RAS mutations to predict resistance to EZH2 inhibi-
tion in SWI/SNF mutant cancer cell lines. Future inhibitors of EZH2
with the ability to disrupt EZH2-PRC2 complex interaction can pre-
sumably be applied in ARID1A, PBRM1 and SMARCA4 mutant cancers
with wild-type RAS.
In other work by Bitler et al. shRNA interference of 11 histone
deacetylases (HDACs) in ARID1Amutant OCCC led to the discovery of a
lethal relationship between ARID1A loss and inhibition of HDAC6, an
epigenetic protein known to deacetylate numerous substrates [48].
Chemical inhibition of HDAC6 with ACY1215 was only eﬀective in an
ARID1A mutant background in a panel of four ARID1A mutant versus
four ARID1A wild-type OCCC cell lines (10-fold lower IC50) and in or-
thotopically transplanted ARID1A mutant xenografts. They further
Fig. 4. ARID1A implicated mechanisms with synthetic lethal opportu-
nities after ARID1A loss. ARID1A itself or incorporated in the SWI/SNF
chromatin remodeling complex is involved in multiple oncogenic suppressive
processes. Therapeutic targeting of these indicated mechanisms were found to
be lethal in an ARID1A mutant background.
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identiﬁed ARID1A as direct transcriptional repressor of HDAC6.
ARID1A loss led to re-expression of HDAC6, which speciﬁcally deace-
tylate p53-lysine120, a residue known to regulate p53-mediated
apoptosis (Fig. 4). Knockdown of TP53 reverted ACY1215 mediated
apoptosis induction and proliferation inhibition in ARID1A mutant
cells, illustrating that ARID1A mutant OCCC speciﬁc ACY1215 sensi-
tivity is p53 dependent. Additional data demonstrated that acetylated
p53-lysine120 localizes to mitochondria and destabilizes mitochondrial
membrane potential, presenting a mechanism for the lethal relationship
between ARID1A loss and HDAC6 inhibition.
Recently, a fourth epigenetic determinant of ARID1A mutation de-
pendent synthetic lethality was identiﬁed by shRNA mediated screening
against all human kinases. In a panel of nine ARID1Amutant versus ﬁve
ARID1A wild-type OCCC cell lines, knockdown of the BET bromodo-
main member BRD2 established speciﬁc lethality in ARID1A mutant
lines [49]. BET bromodomains bind acetylated lysine histone tails and
are involved in transcriptional regulation, but have also been reported
to act as kinases [50, 51]. As a result of high homology between the BET
members BRD2/3/4 and BRDT, only inhibitors that target all four
proteins are available to date. The BET inhibitors JQ1 and iBET762
demonstrated speciﬁc sensitivity in ARID1A mutant OCCC cells, which
was veriﬁed in two ARID1A deﬁcient isogenic OCCC cell line pairs, in
ARID1A mutant OCCC xenografts and patient-derived xenograft
models. Explicitly, ARID1A mutant cells had over two-fold stronger
growth reduction after JQ1 treatment, as observed in the panel of nine
ARID1A mutant versus ﬁve ARID1A wild-type OCCC cell lines. JQ1 or
shRNA mediated inhibition of BRD2 reduced the expression of ARID1B.
Chromatin immunoprecipitation assays indicated direct transcriptional
regulation of ARID1B expression by BRD2 at the ARID1B promoter.
Therefore, the previously described mutual exclusive relation between
ARID1A and ARID1B can at least partially explain the lethal interaction
between BET inhibitor mediated BRD2 inhibition and ARID1A loss
[36]. In addition to ARID1B reduction, more SWI/SNF members were
downregulated at the mRNA level, potentially augmenting to the lethal
phenotype by further reducing the SWI/SNF function. This study pro-
vides a ﬁrst opportunity to chemically inhibit ARID1B expression and
utilize the ARID1A and ARID1B mutual exclusive properties in ARID1A
mutant OCCC.
4.3. Synthetic lethality of ROS induction with ARID1A
Previous observations indicated that SWI/SNF function is required
for oxidative stress resistance in the model organisms Saccharomyces
cerevisiae and Caenorhabditis elegans [52, 53]. A comparison of about
140 drug sensitivities in ARID1Amutant versus wild-type human cancer
cell lines in the “genomics of drug sensitivity in cancer” database
(cancerrxgene.org), encompassing over 700 cancer cell lines, revealed
the HSP90 inhibitor and reactive oxygen species (ROS) inducing agent
elesclomol as the most diﬀerential sensitive drug [54]. Only cell lines
with ARID1A frameshift or nonsense mutations were retained in the
analysis, potentially generating a bias considering the proportion of
cancer patients with this type of ARID1A mutations [9]. Subsequently,
Kwan et al. proved elesclomol sensitivity to be higher in ARID1A mu-
tants in a panel of 11 ovarian cancer cell lines, including four OCCC cell
lines, and three endometrial cancer cell lines [54]. Elesclomol was ﬁve
to six-fold more eﬀective in ARID1A mutant cells compared with
ARID1A wild-type cells and increased ROS levels and apoptosis. Re-
expression of ARID1A induced resistance to elesclomol. Importantly,
knockdown of the SWI/SNF subunits SMARCA4 and SNF5 induced
elesclomol sensitivity in ARID1A wild-type OCCC cells, suggesting that
loss of other SWI/SNF components can predict elesclomol sensitivity as
well. ARID1A knockdown induced intracellular ROS levels in two
ovarian cancer cell lines. A similar observation was made in OCCC
tumor samples where low ARID1A expression was associated with high
expression of 8-hydroxyguanosine, as a marker of oxidative stress [54].
The synthetic lethal ﬁnding by Kwan et al. is not supported by in vivo
data and the mechanisms underlying ROS induction after ARID1A loss
are inconclusive (Fig. 4).
4.4. ARID1A synthetic lethality approaches using dasatinib
In another drug screening study, 68 clinically approved or late-stage
clinically developed inhibitors were screened on three ARID1A wild-
type and eight ARID1A mutant OCCC cell lines [55]. The SRC, ABL and
C-KIT inhibitor dasatinib gave the most speciﬁc inhibitory eﬀect in
ARID1A mutant OCCC cells, demonstrating a more than two-fold in-
creased sensitivity compared to ARID1A wild-type OCCC cells. Dasa-
tinib synthetic lethality was consistently found after ARID1A knock-
down in two OCCC cell lines, one breast cancer cell line and ARID1A
knockout in the cell line HCT116. Using mass spectrometry analysis of
active kinases, ﬁve targets of dasatinib were shown to be upregulated in
ARID1A mutant OCCC cells. The dasatinib target and SRC family pro-
tein YES1 was most selective for ARID1A deﬁcient OCCC cell lines.
Dasatinib treatment increased G1 cell cycle arrest and caspase activity
in ARID1A mutant lines, indicating a cell-cycle arrest/apoptotic phe-
notype. Using siRNA screening, Miller et al. identiﬁed expression of p21
(CIP1/WAF1) and its downstream target RB1 as determinants of dasa-
tinib sensitivity. Dasatinib treatment was previously shown to induce
p21 expression [56]. ARID1A mutant xenograft growth of TOV21G was
reduced after dasatinib treatment, demonstrating therapeutic eﬃcacy
in vivo. Results from this study are consistent with previous research
describing p21 to be regulated via ARID1A [57]. However, Miller et al.
did not indicate a mechanism through which dasatinib could result in
p21 and RB1 induction. Regulation of these two proteins could be
mediated by YES1 or other dasatinib targets.
4.5. Targeting of PI3K/AKT signaling in ARID1A mutant cancers
Results from the Achilles project demonstrated PIK3CA to be the
second best hit for synthetic lethality with ARID1A loss [36]. Accord-
ingly, another analysis from the drug sensitivity in cancer database
from Kwan et al. showed AZD8055, an mTORC1/2 inhibitor that targets
PI3K/AKT signaling downstream, as second best hit in ARID1A mutant
cells in their screen [54]. Both studies suggest a link between ARID1A
loss and PI3K/AKT/mTOR activation. The co-existence of ARID1A
mutations and activation of PI3K/AKT/mTOR signaling has been de-
scribed in multiple cancer types. Signiﬁcant enrichment of PIK3CA
activating mutations and PTEN loss were detected in ARID1A mutant
endometrial cancer. Moreover, knockdown of ARID1A induced phos-
phorylation of the PI3K downstream target AKT [58]. PI3K/AKT
pathway activation occurred after ARID1A depletion in MCF7 breast
cancer cells. These cells gained AKT phosphorylation, and enhanced
sensitivity to AKT and PI3K inhibitors upon ARID1A knockdown. [59].
In OCCC, concurrent PIK3CA activating mutations and PTEN loss were
signiﬁcantly associated with ARID1A mutations, but ARID1A knock-
down did not induce AKT phosphorylation in OCCC cell lines [60, 61].
One study described ARID1A mutant OCCC lines to have lower IC50 for
AKT inhibitors. However, no induction of PI3K/AKT pathway activity
was found in these cells after ARID1A knockdown [59]. Moreover,
ARID1A status could not discriminate between IC50 for PI3K and mTOR
inhibitors in a large panel of OCCC cell lines and PDX models [11].
Some mechanistic links between ARID1A loss and PI3K/AKT
pathway activation have been established. As stated earlier, ARID1A
was found to inhibit PI3K/AKT activity by regulating expression of the
PI3K suppressor PIK3IP1 in ovarian cancer [43]. In breast cancer
ARID1A was identiﬁed as negative transcriptional regulator of ANXA1,
a membrane bound protein and activator of AKT (Fig. 4) [62]. These
two studies suggest that ARID1A loss may indirectly activate PI3K in
some cancer types. Given that PI3K and mTOR inhibitor sensitivity is
not only dependent on ARID1A mutational status in OCCC, targeting
the PI3K/AKT pathway should not be regarded as a synthetic lethal
strategy for ARID1A mutant OCCC.
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5. Clinical development of agents with ARID1A speciﬁc lethality
Multiple agents showing synthetic lethality in an ARID1A mutant
context are in clinical development (Table 1). From the epigenetic
targets with ARID1A mutation speciﬁc lethality in OCCC, the ﬁrst
generation EZH2 inhibitors (DZNep) gave toxicity in vivo. Two novel
EZH2 inhibitors are now in clinical trials [63]. An alternative for EZH2
targeting agents is HDAC2 inhibition using the clinically applicable
broad HDAC inhibitor vorinostat. The HDAC6 inhibitor ACY1215
proved to be well tolerated in myeloma patients, supporting clinical
applicability of HDAC6 inhibition for treating ARID1A deﬁcient OCCC
patients in the future [64]. BET bromodomain inhibition has attracted
great interest for the treatment of cancer. Many BET-inhibitors are
under clinical investigation, and several BET-inhibitors, such as iBET-
762, are currently evaluated in phase II trials. ARID1A status might be a
biomarker to enrich for sensitivity in OCCC and possible other cancer
types as well. Dasatinib is approved for the treatment of leukemia's and
is under investigation in multiple solid tumors. Dasatinib eﬃcacy in
recurrent ovarian cancer patients was limited [65]. However, no se-
lection based on ARID1A status was made. PI3K, PARP and ATR in-
hibitors are being tested in clinical trials for diverse genetic back-
grounds in cancer, utmost in phase III, IV and II respectively.
Considering the advanced clinical development of PI3K and PARP tar-
geting compounds, including trials in ovarian cancer patients, these
agents may provide direct therapeutic opportunities for ARID1Amutant
cancer patients including ARID1A mutant OCCC. Though eﬃcacy
against ARID1A wild-type OCCC should not be excluded.
6. SMARCA2 and SMARCA4-directed synthetic lethal strategies
Aside from synthetic lethal targeting strategies in the context of
ARID1A mutations, the SWI/SNF complex members SMARCA2 and
SMARCA4 have been exploited for this purpose as well. Having
SMARCA2 and SMARCA4 mutations in approximately 2% and 5% of
the tumors, OCCC could beneﬁt from such strategies [15]. In 2013,
Oike et al. described susceptibility for SMARCA2 inhibition in
SMARCA4 deﬁcient non-small cell lung cancer. Treatment with
SMARCA2 siRNA induced markers of senescence in SMARCA4 mutant
cell lines [66]. An epigenome directed shRNA screen further supported
the ﬁnding that SMARCA4 deﬁcient cancers depend on SMARCA2.
SMARCA4/SMARCA2 synthetic lethality was later demonstrated in
multiple other cancer types [67]. SMARCA4 loss resulted in enhanced
integration of SMARCA2 in the residual SWI/SNF complexes, which in
turn may drive oncogenesis [68]. SMARCA2 and SMARCA4 alterations
have a similar incidence in cancer, with the exception of small cell
carcinoma of the ovary hypercalcaemic type (SCCOHT) in which
SMARCA4 mutations are present in 90% of the tumors (Fig. 3). A recent
study reported the absence of SMARCA2 expression in SMARCA4 de-
ﬁcient SCCOHT, indicating that SMARCA2/SMARCA4 mutual ex-
clusivity is not synthetic lethal in all cancer types. Somehow these
cancers have overcome dependency on either one of the SWI/SNF
ATPases. Moreover, restoration of SMARCA2 or SMARCA4 inhibited
proliferation [69]. These results suggest that dependency on SWI/SNF
ATPases is lost in SCCOHT. In line with these observations, another
study identiﬁed several SMARCA4mutant cancers cell lines with absent
or low expression of SMARCA2. Inhibition of the PRC2 subunit EZH2
re-expressed SMARCA2 only in the EZH2 sensitive SMARCA4 mutant
subset of cell lines. EZH2 inhibition speciﬁcally induced apoptosis in
one (the ovarian endometrioid cancer cell line TOV-112D) of the four
EZH2 sensitive SMARCA4 mutant lines [70]. It is unknown whether the
SWI/SNF function is retained after loss of SMARCA2 and SMARCA4 or
that these tumors are more dependent on other chromatin remodelers.
Chemical inhibitors of SMARCA2 and SMARCA4 are currently under
development. The ﬁrst SMARCA2/SMARCA4 speciﬁc inhibitor PFI-3
did not show anti-proliferative eﬀects in lung cancer cells, possibly
because of insuﬃcient inhibition of SMARCA2 binding to DNA [71]. To
utilize the SMARCA2/SMARCA4 dependency in a clinical setting, de-
velopment of inhibitors that target either SMARCA2 or SMARCA4
might be beneﬁcial to achieve tumor selective lethality.
7. Conclusion and future considerations
The abundance of ARID1A loss of function mutations across cancer
types designates mutant ARID1A as an attractive target for synthetic
lethal approaches. Mechanistic insight into inhibitor induced synthetic
lethality with ARID1A loss is at least partially revealed (Fig. 4). EZH2,
HDAC2, HDAC6, BRD2 and YES1 inhibition were found to be speciﬁ-
cally lethal in ARID1Amutant OCCC. Additional lethal targets that have
been veriﬁed across multiple other ARID1A mutant cancer lineages,
included PARP, ATR and HSP90 (Fig. 5).
Inhibition of the synthetic lethal targets HDAC2 and HDAC6 de-
monstrated a large diﬀerence in sensitivity between ARID1A mutant
and wild-type OCCC cell lines. Since both targets were tested in a
limited number of cell lines evaluation in a larger cell line panel of
would be required to verify the robustness of HDAC2 and HDAC6 in-
hibition. Synthetic lethality of drugs targeting EZH2 and BRD2 in
ARID1A mutant OCCC was less pronounced. Though, the advantage of
these last two studies was the use of 3D in vitro models for the as-
sessment of sensitivity to EZH2 inhibition and the use of patient-derived
xenotransplants in addition to a large panel of OCCC cell lines to de-
termine sensitivity to BRD2 inhibition. The distinct function of SWI/
SNF complexes among tissues indicates that molecular dependencies in
ARID1A mutant cancers are lineage speciﬁc, thus requiring testing of
ATR and HSP90 inhibitors in the context of OCCC. For example, PARP
Table 1
Clinical development of agents with ARID1A mutation speciﬁc lethality and their industry names, from ClinicalTrials.gov (http://clinicaltrials.gov).
Molecular target Most advanced clinical phase Compounds in clinical development, most advanced are depicted in bold
EZH2 Phase II EPZ-6438, CPI-1205
HDAC6 Phase II ACY-125, KA2507
BRD2 (BET) Phase II I-BET-762, GSK2820151, RO6870810,
CPI-0610, GS-5829, INCB054329, INCB057643,
ABVV-075, BMS-986158, FT-1101, PLX-51107, SF1126,
CC90010, ZEN003694, BI894999, N-methyl pyrrolidone,
ODM-207
YES1 Phase IV BMS-354825, AZD0530, SKI-606
ATR Phase II VX-970, BAY1895344, AZD6738
PARP1/2 Phase IV AZD2281, ABT-888, BMN673, AG-014699, MK-4827,
SHR3162, SC10914, SOMCL-9112, BGB-290
HSP90 Phase II AT13387, TAS-116, SNX-2112, XL888, PEN-866
PI3Kα/β/δ Phase III BKM120, RP6530, BYL719, PKI-587, AZD8186,
BAY80-6946, TGR-1202, GSK2636771, SF1126,
KA2237, GDC0032, INK1197, GDC-0077, GDZ173,
GS-1101
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inhibitor potency has been evaluated in OCCC cell lines but did not
seem to provide selective sensitivity in ARID1A mutant OCCC cells [11,
72]. We found no enrichment for alterations in DNA repair genes in
ARID1A mutant versus wild-type OCCC tumors and cell lines, which
may provide an explanation for this observation [11]. However, genetic
evidence using isogenic OCCC models still needs to be provided.
Besides, ARID1A was recently assigned an important role in mis-
match repair as it recruits the mismatch repair gene MSH2 to chromatin
during DNA replication. ARID1A loss correlated with mismatch repair
deﬁciency, high mutational load and increased numbers of tumor-in-
ﬁltrating lymphocytes across many human cancer types [73]. These
data propose that ARID1A loss induces microsatellite instability, which
subsequently provides a vulnerability to immunotherapy. In ARID1A
mutant syngeneic mouse ovarian and colorectal cancer models high
susceptibility to immune checkpoint blockade of PD-L1 compared to
isogenic ARID1A wild-type models was already shown [73]. A small
study in OCCC patients found high PD-L1 expression and more tumor
inﬁltrating lymphocytes in microsatellite instable cancers, but the
ARID1A mutation status was not determined [74]. However, the fre-
quency of microsatellite instability in OCCC is relatively low (10–14%),
implying that the percentage of OCCC tumors with microsatellite in-
stable and ARID1A loss will be even lower [74, 75]. Taken together,
these results support exploring immunotherapeutic approaches in the
context of ARID1A mutant OCCC and could be relevant for a small
subset of OCCC patients (Fig. 5).
The question remains whether direct targeting of ARID1B in an
ARID1A mutant context in OCCC is feasible. It will be challenging to
chemically inhibit ARID1B, since both ARID1A and ARID1B lack ac-
tionable ATPase or catalytic domains. Moreover, in several OCCC tu-
mors mutations in both ARID1A and ARID1B were observed, suggesting
that in these cells some expression of ARID1A or ARID1B was retained,
the SWI/SNF complex is no longer active or compensatory proteins
have taken over the DNA binding function of ARID1A and ARID1B
within the SWI/SNF complex [15]. Synthetic lethality in SMARCA2 or
SMARCA4 mutant OCCC may be an alternative strategy. However,
limited results indicate context dependency of loss of SMARCA2 and
SMARCA4 as well, but this has not been investigated in the context of
OCCC. Important questions are whether inhibitors selective for either
SMARCA2 or SMARCA4 can be developed and which other targets can
be used for synthetic lethality approaches in the context of SMARCA2
or SMARCA4 loss in OCCC.
ARID1A mutation directed lethal strategies using agents in clinical
development are becoming feasible in ARID1A mutant OCCC.
Ultimately, simultaneous inhibition of multiple synthetic lethal targets
in ARID1A mutant OCCC should be assessed to overcome the onset of
resistance toward single target synthetic lethality.
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